Nitroso Duloxetine Impurity

Nitroso Duloxetine Impurity is a nitrosamine-related impurity that can form from Duloxetine through nitrosation of its N-methyl amino group. As a member of the nitrosamine class of compounds, it is considered a potentially genotoxic impurity and is subject to heightened regulatory attention due to the potential carcinogenic risk associated with nitrosamine exposure. Duloxetine is a serotonin–norepinephrine reuptake inhibitor (SNRI) widely used for the treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and other chronic pain conditions.

This impurity may be generated during active pharmaceutical ingredient (API) synthesis, formulation manufacturing, or storage when nitrite-containing materials, acidic conditions, oxidizing agents, or other nitrosating factors are present. Therefore, pharmaceutical manufacturers are expected to evaluate the risk of its formation and implement suitable control strategies throughout the product lifecycle. Monitoring and controlling this impurity is an essential part of nitrosamine risk management programs designed to ensure product quality, regulatory compliance, and patient safety.

Nitroso Duloxetine Impurity has the Cas no 3078587-36-4 ,molecular formula C₁₈H₁₈N₂O₂S and a molecular weight of 326.41 g/mol. In accordance with current regulatory expectations for nitrosamine impurities with limited compound-specific toxicological data, its control is generally guided by risk-based frameworks established by global regulatory agencies, including the U.S. Food and Drug Administration, the European Medicines Agency, and the International Council for Harmonisation.

Manasa Life Sciences, headquartered in Hyderabad, is a manufacturer and supplier of high-purity nitrosamine impurity reference standards for pharmaceutical and research applications worldwide. The company supports nitrosamine control strategies through certified reference standards, risk assessment services, and the development and validation of advanced LC-MS/MS and GC-MS analytical methods, enabling accurate detection, quantification, and control of nitrosamine impurities to ensure regulatory compliance and patient safety.